Okay, let's tackle this question. The question is about the enteroinsular axis and what mediates it. First, I need to recall what the enteroinsular axis refers to. From what I remember, the enteroinsular axis involves the interaction between the gastrointestinal tract and the pancreas, particularly in regulating insulin secretion.

The main hormone I associate with this is GLP-1 (Glucagon-like peptide-1). GLP-1 is released from the intestinal L-cells in response to food intake, especially carbohydrates and fats. It then acts on the pancreatic beta cells to stimulate insulin release. This makes sense because the enteroinsular axis is about how the gut hormones influence insulin secretion, which is part of the incretin effect.

Now, looking at the options (even though the options aren't listed here, I'll assume typical distractors). Common options might include other gut hormones like GIP (Glucose-dependent insulinotropic polypeptide), CCK (Cholecystokinin), or maybe something like GLP-2 or others.

GLP-1 is definitely a key player here. GIP is another incretin hormone, but the question is about the enteroinsular axis. However, some sources might mention both GIP and GLP-1 as part of the incretin system, but the enteroinsular axis specifically refers to the gut-to-pancreas communication. So, if the options included GLP-1, that's the correct answer.

Other options like CCK are more involved in gallbladder contraction and digestion, not insulin. GLP-2 is involved in intestinal growth. So those would be incorrect.

The core concept here is the role of GLP-1 in mediating the enteroinsular axis by stimulating insulin secretion from the pancreas in response to gut hormones. The clinical pearl is that GLP-1 agonists are used in diabetes management because they enhance this axis's function.

**Core Concept**
The enteroinsular axis describes the communication between the gastrointestinal tract and the pancreatic islets of Langerhans, primarily mediated by gut hormones to regulate insulin secretion. *Glucagon-like peptide-1 (GLP-1)* is the key mediator in this axis, released from intestinal L-cells in response to nutrient ingestion.

**Why the Correct Answer is Right**
GLP-1 is secreted by the distal small intestine and colon after meals. It binds to GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion via cAMP-dependent pathways. This mechanism underlies the *incretin effect*, where oral glucose stimulates more insulin than intravenous glucose. GLP-1 also suppresses glucagon release and slows gastric emptying, further modulating postprandial glucose levels.

**Why Each Wrong Option is Incorrect**
**Option A:** *Cholecystokinin (CCK)* stimulates gallbladder contraction and pancreatic enzyme secretion but does not mediate the enteroinsular axis.
**Option B:** *Glucose-dependent insulinotropic polypeptide (GIP)* is another incretin, but it acts on pancreatic alpha and beta cells independently of the enteroinsular axis framework.
**Option C:** *Secretin* regulates pancreatic bicarbonate secretion and is not directly involved in insulin release.
**Option D:** *Glucagon-like

✓ Correct Answer: B. GLP-1